Accordingly, pharmacological inhibitors of Trk and ALK RTKs are being tested in clinical trials in neuroblastoma (Lange and Lo, 2018; Pacenta and Macy, 2018; Higashi et al., 2019). The gene discussed is ALK; the disease is neuroblastoma.